Friday, September 23, 2016 11:15:08 AM
Nice analysis, I like your comment, and I like to add to it, if I may. I myself believe that NorthWest Bio is near the completion of their phase III study trial. Why bring in a big partner when you know you have a very good hand the best hand at the table. You just don't have any money to raise your hand, but you have a damn good hand and no more money left to raise the pot. If you take the money from someone else, they're going to want half of the winning, because they know you have the winning hand (a product that is favorable for an FDA approval). The best hand at the table. Now you can cut them in, or raise more funds by selling cheap warrants and piss off your shareholders, or take a gamble and show someone else your hand for a smaller piece of the pot.
A very hard decision, but you have to do something, because you need the extra money to raise the pot. The money on the table is not enough to complete the clinical trial and you want all of those winning for your company and shareholders. You did the hardest work why share this development with another company who have did nothing but give you all the funds you need to complete the clinical trial and they get half. I say throw that land you have in UK into the pot and call it a day.
A very hard decision, but you have to do something, because you need the extra money to raise the pot. The money on the table is not enough to complete the clinical trial and you want all of those winning for your company and shareholders. You did the hardest work why share this development with another company who have did nothing but give you all the funds you need to complete the clinical trial and they get half. I say throw that land you have in UK into the pot and call it a day.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
